Stati Uniti - inglese - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - ciprofloxacin 3 mg in 1 ml - ciprodex is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: - acute otitis media in pediatric patients (age 6 months and older) with tympanostomy tubes due to staphylococcus aureus , streptococcus pneumoniae , haemophilus influenzae , moraxella catarrhalis , and pseudomonas aeruginosa . - acute otitis externa in pediatric (age 6 months and older), adult and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa . - ciprodex is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components in this medication. - use of this product is contraindicated in viral infections of the external canal including herpes simplex infections and fungal otic infections. teratogenic effects. pregnancy category c: no adequate and well controlled studies with ciprodex have been performed in pregnant women. caution should be exercised when ciprodex

Canada - inglese - Health Canada

taro pharmaceuticals inc - ciprofloxacin (ciprofloxacin hydrochloride); dexamethasone - suspension - 0.3%; 0.1% - ciprofloxacin (ciprofloxacin hydrochloride) 0.3%; dexamethasone 0.1% - antibacterials

Canada - inglese - Health Canada

sandoz canada incorporated - ciprofloxacin (ciprofloxacin hydrochloride); dexamethasone - suspension - 0.3%; 0.1% - ciprofloxacin (ciprofloxacin hydrochloride) 0.3%; dexamethasone 0.1% - antibacterials

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - dexamethasone; ciprofloxacin hydrochloride - ear drops - 1mg/1ml ; 3mg/1ml

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

consilient health ltd - dexamethasone; ciprofloxacin hydrochloride - ear drops - 1mg/1ml ; 3mg/1ml

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - dexamethasone; ciprofloxacin hydrochloride - ear drops - 1mg/1ml ; 3mg/1ml

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - dexamethasone; ciprofloxacin hydrochloride - ear drops - 1mg/1ml ; 3mg/1ml

Stati Uniti - inglese - NLM (National Library of Medicine)

fresenius kabi usa, llc - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 4 mg in 1 ml - - intravenous or intramuscular administration. when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: endocrine disorders. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is

Stati Uniti - inglese - NLM (National Library of Medicine)

vedco, inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indcated for  the treatment of primary bovine ketosis an as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of vairious rheumatic, allergic dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids.  dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immeidate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ktosis.  the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularyly, are generally noted within the first 5 to 12 hours.  when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner.  blood sugar levels rise to normal levels repidly and genreally rise to above normal levels within 12 to 24 hours.  acetone bodies are reduce to normal concentrations usually witnin 24 hours.  th

Stati Uniti - inglese - NLM (National Library of Medicine)

clipper distributing company, llc - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - dexamethasone 2 mg in 1 ml - dexamethasone injection 2 mg/ml is indicated for the treatment of primary bovine ketosis and as an anti-inflammatory agent in the bovine and equine. as supportive therapy, dexamethasone injection 2 mg/ml may be used in the management of various rheumatic, allergic, dermatologic, and other diseases known to be responsive to anti-inflammatory corticosteroids. dexamethasone injection 2 mg/ml may be used intravenously as supportive therapy when an immediate hormonal response is required. bovine ketosis dexamethasone injection 2 mg/ml is offered for the treatment of primary ketosis. the gluconeogenic effects of dexamethasone injection 2 mg/ml, when administered intramuscularly, are generally noted within the first 6 to 12 hours. when dexamethasone injection 2 mg/ml is used intravenously, the effects may be noted sooner. blood sugar levels rise to normal levels rapidly and generally rise to above normal levels within 12 to 24 hours. acetone bodies are reduced to normal concentrations usually within 24 hours. the p